BioNTech’s Bold Transition from Pandemic Savior to Cancer Crusader
BioNTech transitions from COVID-19 vaccine success to pioneering mRNA-based cancer therapies. The company aims for its first market approval for cancer treatments by 2026, focusing on bladder and colorectal cancers.…